Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.

Autor: Caocci, Giovanni, Mulas, Olga, Mantovani, Daniela, Costa, Alessandro, Galizia, Andrea, Barabino, Luca, Greco, Marianna, Murru, Roberta, La Nasa, Giorgio
Předmět:
Zdroj: Annals of Hematology; Apr2022, Vol. 101 Issue 4, p929-931, 3p
Abstrakt: Dear Editor, The COVID-19 pandemic has infected over 150,000 million people worldwide, causing approximately 3 million deaths, and a worldwide effort was made to develop efficient vaccines for this disease [[1]]. A diagnosis of primary MF was performed in 13 cases (65%), post-essential thrombocythemia MF in 6 (30%) patients, and post-polycythemia vera MF in 1 (5%) patient. [Extracted from the article]
Databáze: Complementary Index